Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27420852 | 0.98 | ALDH1A1 (0.39) | ALDH1A1GPR119P2RX7GABRA1GABRG2 | |
| SCHEMBL27956784 | 0.81 | GPR119 (0.38) | ALDH1A1GPR119GABRA1GABRG2GABRB3 | |
| SCHEMBL30587673 | 0.79 | P2RX7 (0.41) | ALDH1A1P2RX7HSD17B10KDM4EHPGD | |
| SCHEMBL7159196 | 0.78 | ALDH1A1 (0.37) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL642470 | 0.78 | ALDH1A1 (0.37) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL165564 | 0.77 | ATR (0.38) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30371874 | 0.77 | ALOX15 (0.38) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL25659580 | 0.77 | ALOX15 (0.38) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3366139 | 0.77 | HPGDS (0.40) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2652708 | 0.76 | ALDH1A1 (0.55) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-110062758-B | Bicyclic dihydropyrimidine-carboxamide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-107667107-B | Ethynyl derivatives | 豪夫迈·罗氏有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-100335479-C | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2007-09-05 | — | — | CN | disclosed |
| US-7205310-B2 | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2005111020-A2 | PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261324-A1 | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| CN-1434824-A | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2003-08-06 | — | — | CN | disclosed |
| EP-1303503-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| CN-1100425-A | Thiazolopyrimidine derivatives | DAIICHI SEIYAKU CO (JP) | 1995-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261324-A1 | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, LPAR4 | ALDH1A1 280/4885GPR119 414/4885P2RX7 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.